Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 4, 2017

Glenmark receives IND application clearance to begin Phase I trial of GBR 1302-BEAT for HER2+ cancer

The US Food and Drug Administration (FDA) has cleared pharmaceutical company Glenmark’s investigational new drug (IND) application to begin a phase I trial of GBR 1302-BEAT to treat HER2+ cancers.

The US Food and Drug Administration (FDA) has cleared pharmaceutical company Glenmark’s investigational new drug (IND) application to begin a phase I trial of GBR 1302-BEAT to treat HER2+ cancers.

Bi-specific engagement by antibodies based on the T-cell receptor (BEAT) has been designed to produce bi-specific antibodies (bsAbs) that engage with two targets to affect cancer cells, which in the case of HER2+ cancers redirects cytolitic T-cells.

Glenmark president and chief medical officer Fred Grossman said: “We believe GBR 1302 may have utility across a broad range of HER2+ tumour types.

“Data from preclinical studies are very encouraging.

"We believe GBR 1302 may have utility across a broad range of HER2+ tumour types."

“Based on its novel mechanism of redirecting T-cells to HER2+ cancer cells, GBR 1302 has the potential to become an important therapy for previously treated and, eventually, newly diagnosed HER2+ tumours.”

The phase I trial will be carried out in two parts, the dose escalation and expansion.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The dose-escalation will examine patients with previously treated HER2+ tumours in order to test safety and tolerability, as well as the pharmacokinetics and preliminary anti-tumour activity of the maximum dose of GBR 1302-BEAT .

The expansion will examine the same population treated with the maximum tolerated dose to determine early proof-of-concept.

Preclinical studies suggested that GBR 1302 is supposedly active against a range of HER2-expressing tumour types, including breast, gastric and other cancers.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU